— Know what they know.
Not Investment Advice

NWBO OTC

Northwest Biotherapeutics, Inc.
1W: -7.0% 1M: +19.8% 3M: -3.2% YTD: -8.8% 1Y: -19.6% 3Y: -61.9% 5Y: -86.4%
$0.23
+0.00 (+0.30%)
 
Weekly Expected Move ±9.4%
$0 $0 $0 $0 $0
OTC · Healthcare · Biotechnology · Alpha Radar Buy · Power 56 · $383.6M mcap · 1.61B float · 0.190% daily turnover · Short 41% of daily vol
Smart Money Score
Watch 25
Insider
Congress
ETF Holdings
Key Statistics
Market Cap$383.6M
52W Range0.19-0.37
Volume1,034,051
Avg Volume3,044,448
Beta-0.74
Dividend
Analyst Ratings
0 Buy 1 Hold 0 Sell
Consensus Hold
Company Info
CEOLinda F. Powers
Employees25
SectorHealthcare
IndustryBiotechnology
IPO Date2001-12-14
Websitenwbio.com
4800 Montgomery Lane
Bethesda, MD 20814
US
240 497 9024
About Northwest Biotherapeutics, Inc.

Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.

Recent Insider Trades

NameTypeSharesPriceDate
BOYNTON ALTON L G-Gift 1,000,000 $0.23 2024-08-29
BOSCH MARNIX L G-Gift 3,000,000 $0.35 2024-08-09
BOYNTON ALTON L G-Gift 1,000,000 $0.23 2024-08-08
MALIK NAVID S-Sale 657,895 $0.23 2024-07-26
MALIK NAVID S-Sale 150,000 $0.82 2023-11-17

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms